Policy & Compliance

  • April 29, 2026

    CEO Stole From His Company To Buy Mansion, SEC Says

    The former CEO of a California-based pharmaceutical company agreed Wednesday to pay the U.S. Securities and Exchange Commission $30,000 to end a lawsuit accusing him of misappropriating $3.2 million in company funds partly to buy a Beverly Hills mansion.

  • April 29, 2026

    Novo Nordisk Rejects Claim It Influences GLP-1 Market

    Pharmaceutical giant Novo Nordisk told a Texas federal judge that it does not control the GLP-1 market and has not attempted to crush its competition in a bid to dismiss an antitrust suit it is facing.

  • April 29, 2026

    PBMs Say Michigan AG Price-Fixing Suit Is Unsound

    Pharmacy benefit managers Express Scripts, Evernorth Health and Prime Therapeutics have bolstered their effort to escape a federal price-fixing suit brought against them by Michigan's attorney general by arguing the statutes cited in the complaint do not apply to them.

  • April 29, 2026

    Mass. AG, Insurer Settle Deceptive Marketing Claims For $5M

    A Texas-headquartered health insurance agency will pay $5 million to settle allegations that it engaged in deceptive and unfair marketing to sell plans and other types of health programs to thousands of Massachusetts consumers, the state's attorney general announced on Wednesday.

  • April 29, 2026

    5th Circ. Will Rehear Aetna Arbitration Bid In Aramark Suit

    The full Fifth Circuit will reconsider insurance company Aetna's bid to force uniform and food services company Aramark to arbitrate its dispute over employee health benefit claims, staying a panel's ruling from December that had kept proceedings in court.

  • April 29, 2026

    AbbVie Seeks Early Win Over HHS In Botox Drug Price Suit

    When the federal government included Botox in Medicare's drug price negotiation program, which allows Medicare officials to negotiate for lower drug prices, it overstepped its authority, drugmaker AbbVie Inc. told a D.C. federal court, arguing the cosmetic drug and migraine treatment is a "plasma-derived" product ineligible for price controls.

  • April 29, 2026

    Medical Equipment Co. Settles Patient Overbilling Claims

    Patients who claim Pennsylvania-based AdaptHealth Corp. overcharged them for returned medical equipment have reached the final version of a class settlement and will soon submit it to a North Carolina federal court for approval, they told the court this week.

  • April 29, 2026

    Justices Rule NJ Info Demand Chilled Anti-Abortion Speech

    The U.S. Supreme Court on Wednesday unanimously revived an anti‑abortion pregnancy center network's constitutional challenge to a New Jersey subpoena seeking years of donor information, holding that the state's demand infringed free speech.

  • April 28, 2026

    Ohio Justices Nix 'Would Have Been Married' Obergefell Test

    The Ohio Supreme Court held Tuesday that a state law establishing parental rights for the spouse of a woman who conceives a child through artificial insemination doesn't retroactively apply to same-sex couples when a child was born before gay marriage was legalized by the U.S. Supreme Court in 2015.

  • April 28, 2026

    Ex-Fauci Adviser Charged With Concealing COVID Records

    Federal prosecutors have charged a former adviser to Dr. Anthony Fauci with deleting government emails and using his personal email account to dodge public records requests about the origins of the COVID-19 virus.

  • April 28, 2026

    Purdue Pharma's $5.5B Plea Deal Clinched As Survivors Protest

    OxyContin maker Purdue Pharma LP has to pay a $3.5 billion fine and forfeit an additional $2 billion, more than five years after it pled guilty to criminal charges related to its role in the opioid crisis, a New Jersey federal judge said Tuesday.

  • April 28, 2026

    As RFK Jr. Touts Peptides, Industry Eyes Regulatory Hurdles

    Compounding pharmacies eager to cash in on the peptide boom are watching closely as the nation’s top health official pushes to legalize the market. A regulatory minefield may mean a long wait.

  • April 28, 2026

    Attys Want To See Examples In New Mental Health Parity Rule

    The Trump administration's plans to promulgate new regulations governing mental health parity requirements for employee health plans are currently causing headaches for attorneys, but a rule that includes specific examples could ultimately ease compliance burdens for benefit plan sponsors.

  • April 28, 2026

    MedMal Case Volume Declines, But Doctor Risks Remain High

    While the volume of malpractice lawsuits against U.S. physicians has dropped in recent years, that doesn't mean the threat of legal liability is dissipating, according to a report released Monday by the American Medical Association. 

  • April 28, 2026

    Mich. Health System Inks $1.9M Deal To End ERISA Suit

    A Michigan health system agreed to pay $1.9 million to resolve a suit claiming it failed to kick an underperforming investment fund from its workers' retirement plan, causing employees to lose out on millions in savings.

  • April 28, 2026

    La. AG On 340B, Comstock And 'Political Act' Of Abortion Pills

    Louisiana's attorney general has sued over mifepristone, pursued charges against out-of-state doctors and sparred with drugmakers. Liz Murrill talks to Law360 Healthcare Authority about her approach to healthcare and the law.

  • April 28, 2026

    Union Urges Toss Of Tobacco Co.'s Retiree Health Fight

    A North Carolina federal judge should let a tobacco workers' union keep its win in a retiree healthcare fight with the company that makes Winston and Salem cigarettes, the union argued, saying the company's challenge to a November arbitration award can't proceed because it wasn't properly filed.

  • April 28, 2026

    Maryland Justices Allow IVF Cost Class Action To Proceed

    A Maryland couple can pursue a proposed class action against a health insurer that they say wrongfully denied coverage for embryo thawing in connection with an in vitro fertilization procedure, the Maryland Supreme Court has ruled, finding that the insurer's subsequent payment of the claim doesn't moot the suit.

  • April 28, 2026

    Meet The Attys Arguing The High Court 'Skinny Label' Case

    When the U.S. Supreme Court hears arguments Wednesday in a patent case involving "skinny labels" on generic drugs, a longtime patent attorney as well as a government attorney who often handles intellectual property cases will face an appellate specialist who has argued many high court cases.

  • April 27, 2026

    North Dakota Drug-Pricing Law Blocked In Pharma Fight

    A North Dakota federal judge on Monday blocked the state's new drug-pricing law, agreeing with pharmaceutical companies that while the law purports to "protect the underdogs," it illegally interferes with the federal drug-pricing regime.

  • April 27, 2026

    DOJ Says Wash. 340B Drug Law Is Preempted In Novartis Suit

    The U.S. Department of Justice waded into a dispute between pharmaceutical giants and the state of Washington on Monday, arguing that federal law preempts a new state law that expands discounts that drugmakers must provide under the federal 340B Drug Pricing Program.

  • April 27, 2026

    Wyoming's Latest Near-Total Abortion Ban Blocked

    A Wyoming judge has blocked enforcement of the latest effort by state lawmakers to enact a rigid anti-abortion law, after the Wyoming Supreme Court in January struck down the state's previous near-total ban on abortion. 

  • April 27, 2026

    'General Hospital' Actor Can't Revive Vax Suit Against ABC

    California appellate justices refused to reinstate a "General Hospital" actor's suit alleging ABC fired him for his political views after he declined to comply with its COVID-19 vaccine policy, ruling the evidence shows that the ultimate decision-makers who ended his employment agreement didn't know about his political views.

  • April 27, 2026

    Bioscience Co. Allegedly Hid Volatility Risks From Investors

    A company purportedly focused on using traditional Chinese medicine to treat conditions including autism spectrum disorder faces a proposed investor class action alleging it downplayed the risk it would be probed in connection with unusual volatility affecting the market for its shares.

  • April 27, 2026

    4th Circ. Says Medicaid Fraud Convictions Lacked Evidence

    The government failed to prove the former owner of a mental health counseling company in Virginia willfully committed fraud by falsely billing Medicaid $200,000 for counseling services on two specific dates, a panel of the Fourth Circuit has found, overturning his convictions.

Expert Analysis

  • Employer Considerations After 11th Circ. Gender Care Ruling

    Author Photo

    The Eleventh Circuit's en banc decision in Lange v. Houston County, Georgia, finding that a health plan did not violate Title VII by excluding coverage for gender-affirming care, shows that plans must be increasingly cognizant of federal and state liability as states pass varying mandates, say attorneys at Miller & Chevalier.

  • How Healthcare Practices Can Prepare For ICE Visits

    Author Photo

    Healthcare providers that may face encounters with immigration enforcement should familiarize themselves with compliance obligations beyond ensuring employment authorization, and mitigate risk by establishing clear policies and specific procedures that safeguard patient rights and manage staff interactions with agents, say attorneys at Roetzel & Andress.

  • Adapting To Calif.'s Enhanced Regulation Of PE In Healthcare

    Author Photo

    New California legislation enhances oversight on the role of private equity groups and hedge funds in healthcare transactions, featuring both a highly targeted nature and vague language that will require organizations to carefully evaluate existing practices, says Andrew Demetriou at Husch Blackwell.

  • Lessons From 7th Circ. Decision Affirming $183M FCA Verdict

    Author Photo

    The Seventh Circuit's decision to uphold a $183 million False Claims Act award against Eli Lilly engages substantively with recurring materiality and scienter questions and provides insights into appellate review of complex trial court judgments, say Ellen London at London & Naor, Li Yu at Bernstein Litowitz and Kimberly Friday at Osborn Maledon.

  • Calif. Justices Continued Anti-Arbitration Trend This Term

    Author Photo

    In the 2024-2025 term, the California Supreme Court justices continued to narrow arbitration's reach under state law, despite state courts' extreme caseload backlog and even as they embraced contractual autonomy in other contexts, says Josephine Petrick at The Norton Law Firm.

  • Steps For Healthcare Providers After Cigna ERISA Settlement

    Author Photo

    Following the Cigna class action's settlement, where Employee Retirement Income Security Act violations arose from Cigna's online provider directory advertising providers as in-network who were actually out-of-network, providers should routinely audit their contract status and directory listings, and proactively coordinate with plans and payor partners, say attorneys at ArentFox Schiff.

  • What's New In FDA's Latest Cell And Gene Therapy Guidance

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration, along with other recent initiatives, come together to promote cell and gene therapy product development by streamlining development and review pathways, say attorneys at Holland & Knight.

  • Adapting To Enforcement Focus On Wound Care Fraud

    Author Photo

    As federal agencies target wound care industry fraud as a top enforcement priority, attorneys advising industry stakeholders should evaluate business relationships for Anti-Kickback Statute violations, emphasize appropriate product use and documentation, and use internal data analytics to monitor billing patterns, say David Tarras at Tarras Defense and Jay McCormack at Verrill Dana.

  • AG Watch: Illinois A Key Player In State-Level Enforcement

    Author Photo

    Illinois Attorney General Kwame Raoul has systematically strengthened his office to fill federal enforcement gaps, oppose Trump administration mandates and advance state policy objectives, particularly by aggressively pursuing labor-related issues, say attorneys at Troutman.

  • Organ Transplant System Reforms Mark Regulatory Overhaul

    Author Photo

    Recent oversight, enforcement and operational developments in the U.S. organ procurement and transplantation system, alongside challenges like the federal shutdown, highlight heightened regulatory scrutiny and the need for compliance to maintain public trust, say attorneys at Hall Render.

  • Federal Grantees May Soon Face More Limitations On Speech

    Author Photo

    If courts accept the administration’s new interpretation of preexisting case law, which attempts to graft onto grant recipients the existing limitations on government contractors' free speech, a more deferential standard may soon apply in determining whether an agency’s refusal or termination of a grant was in violation of the First Amendment, say attorneys at Venable.

  • HHS Wound Care Report Highlights Need For Payment Reform

    Author Photo

    The U.S. Department of Health and Human Services' recent report on potential abuse in Medicare Part B payments for skin substitutes highlights specific fraud schemes, but more importantly emphasizes that broader changes are needed for the wound care sector's fundamentally flawed payment system, say attorneys at Paul Hastings.

  • Assessing The Future Of The HIPAA Reproductive Health Rule

    Author Photo

    In light of a Texas federal court's recent decision to strike down a U.S. Department of Health and Human Services rule aimed to protect the privacy of patients seeking abortions and gender-affirming care, entities are at least temporarily relieved from compliance obligations, but tensions are likely to continue for the foreseeable future, says Liz Heddleston at Woods Rogers.